Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2026)
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther (in press)
DOI 10.1016/j.ymthe.2026.09.027, PubMed 42800469

Gondaliya P, Zinn DA, Sayyed AA, Driscoll J, Yan IK, Mensali N, Wälchli S, Patel T (2026)
Engineered Natural Killer Cell Derived-Extracellular Vesicles: An Acellular Immunotherapy with Cytotoxic Effects in SNU-1079 Human Cholangiocarcinoma Cells
Mol Pharm, 23 (9), 4540-4552
DOI 10.1021/acs.molpharmaceut.6c00219, PubMed 42704135

Krawczyk M, Fidyt K, Fernandez-Fuentes N, Winiarski T, Pepek M, Bousquets-Muñoz P, Puente XS, Gutiérrez-Fernández A, Davis J, Owczarek D, Graczyk-Jarzynka A, Sanz-Galarreta P, Menendez P, Szumera-Ciećkiewicz A, Benard E, Wälchli S, Thomas-Tikhonenko A, Pérez-García VM, Galán-Gómez V, Escudero López A, Delgado EI, Minguillón J, Pérez-Martínez A, Winiarska M (2026)
Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy
Leukemia (in press)
DOI 10.1038/s41375-026-03081-3, PubMed 42660975